The FDA has rejected Sanofi's application seeking approval of tolebrutinib to treat certain forms of MS in its present form.

MS research suggests the disease may be divided into two biological subtypes that differ in how early and aggressively nerve ...

Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...

A long-term study has identified a potential biomarker that could help detect which patients are progressing toward more severe forms of multiple sclerosis.

The festive period brought some unwanted post for both Sanofi and Corcept Therapeutics in the form of FDA rejections for the ...

Multiple sclerosis-secondary progressive multi-arm randomisation trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three ...

Multiple sclerosis (MS) is a chronic autoimmune disease in which the immune system attacks the body’s nerves. Immune cells ...

Multiple sclerosis (MS) is a disorder that prompts the body's immune system to attack myelin, the protective sheath covering nerve cells in the brain, optic nerve and spinal cord. This can in turn ...

Many people with multiple sclerosis struggle with balance and coordination, and this study uncovers a hidden reason why.

Early studies of biotin as a treatment for multiple sclerosis (MS) were promising, showing that it was well tolerated and brought sustained reversal of MS-related disability. More recent studies, ...

The SPRINT-MS trial evaluated the novel drug ibudilast over 96 weeks in patients with primary and secondary progressive multiple sclerosis. The SPRINT-MS trial was a phase II clinical trial of ...